Exact Mass: 388.25214080000006
Exact Mass Matches: 388.25214080000006
Found 500 metabolites which its exact mass value is equals to given mass value 388.25214080000006,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
6beta-Hydroxytestosterone diacetate
11alpha-Hydroxytestosterone diacetate
5,6-Dihydroxyprostaglandin F1a
Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs) and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes) and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signaling pathways. [HMDB] Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways.
Cavipetin C
Cavipetin C is found in mushrooms. Cavipetin C is a constituent of the edible mushroom Boletinus cavipes Constituent of the edible mushroom Boletinus cavipes. Cavipetin C is found in mushrooms.
3-keto-Digoxigenin
3-keto-Digoxigenin is a metabolite of digoxin. Digoxin is a purified cardiac glycoside and extracted from the foxglove plant, Digitalis lanata. Its corresponding aglycone is digoxigenin, and its acetyl derivative is acetyldigoxin. Digoxin is widely used in the treatment of various heart conditions, namely atrial fibrillation, atrial flutter and sometimes heart failure that cannot be controlled by other medication. Digoxin preparations are commonly marketed under the trade names Lanoxin, Digitek, and Lanoxicaps. (Wikipedia)
7alpha-hydroxy-3-oxochol-4-en-24-oic Acid
7alpha-hydroxy-3-oxochol-4-en-24-oic Acid is also known as 3-oxo-7-Hydroxychol-4-enoic acid or 7-HOC acid. 7alpha-hydroxy-3-oxochol-4-en-24-oic Acid is considered to be practically insoluble (in water) and acidic. 7alpha-hydroxy-3-oxochol-4-en-24-oic Acid is a bile acid lipid molecule D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids 3-Oxo-7-hydroxychol-4-enoic acid is an endogenous metabolite. 3-Oxo-7-hydroxychol-4-enoic acid may be an important indicator of a poor prognosis in hepatobiliary disease[1].
Corticosterone acetate
CID 92044469
Ingenol-5,20-acetonide is an intermediate from ingenol for synthesis of ingenoids; improved stability compared to ingenol.
(ent-13E,14E)-15,16-Diacetoxy-7,13(16),14-labdatriene
5,19-Epoxy-19-methoxy-20,21,22,23,24,25,26,27-octanorcucurbitane-3,7,17-trione
3beta,5-Dihydroxy-14,15beta-epoxy-5beta,14beta-card-20(22)-enolid
17-hydroxy-10E-centipedic acid methyl ester acetate
rel-(1R,5R)-2-(1-farnesyl-5-hydroxy-2-oxocyclohex-3-en-1-yl)-acetic acid methyl ester
3beta,14-Dihydroxy-19-oxo-5beta,14beta-card-20(22)-enolid|3beta,14-dihydroxy-19-oxo-5beta,14beta-card-20(22)-enolide|Cannogenin|cardenolide|Corotoxigenin
(19R)-5beta,19-epoxy-19-methoxy-20,21,22,23,24,25,26,27-octanorcucurbit-6-ene-3,17-dione|octanorcucurbitacin D
Tanghinigenin
A member of the class of cardenolides that is 7,8-epoxycard-20(22)-enolide substituted by hydroxy groups at positions 3 and 14 (the 3beta,5beta,7beta stereoisomer).
(1R*,3S*,4R*,6S*)-9-(Acetoxy)-4-hydroxy-1-[(2Z)-2-methylbut-2-enoyloxy]bisabol-10(11)-ene|18-Acetoxy-15??-hydroxymansumbinone|28-acetoxy-15alpha-hydroxymansumbinone
rel-(3S,1R,2S)-3-(1-farnesyl-2-hydroxy-4-oxocyclopentan-1-yl)-3-methoxypropanoic acid lactone
15alpha-isobutyroyloxykaur-16-en-19-oic acid|15alpha-isobutyryloxy-ent-kaurenic acid
butyl (2Z)-2-[(1R,4E,10E,14R)-4,10,14-trimethyl-6-oxo-15-oxabicyclo[12.1.0]pentadeca-4,10-dien-7-ylidene]propanoate|secosarcophinolide
4-methoxy-6-ethoxy-2-[(8Z,11Z)-8,11,14-pentadecatriene]resorcinol
2alpha,19-diacetoxy-9-epi-ent-pimara-7,15-diene|Di-Ac-7,15-Pimaradiene-2,18-diol
Hexahydro-4-methoxy-4a-(3, 7, 11-trimethyl-2, 6, 10-dodecatrienyl)-cyclopenta[b]pyran-2, 6-dione, 9CI
(-) Kauren-7beta,18-diacetat|ent-7alpha,18-diacetoxykaur-16-ene|epicandicandiol di-acetate|Epicandicandiol diacetate|Epicandicandioldiacetat
(1E,6E)-3-[(E)-acetoxymethylidene]-7-methyl-9-(2,6,6-trimethylcyclohex-2-enyl)nona-1,6-dienyl acetate
ent-14beta-tigloyloxy-19-norbeyer-15-en-19-hydroperoxide
6beta,18-diacetoxycassan-13,15-diene|6beta,18-dihydroxycassan-13,15-diene diacetate
Palmitoleoyl 3-carbacyclic Phosphatidic Acid
C20H37O5P (388.23784820000003)
3,6-Dioxo-5b-cholan-24-oic acid
BA-115-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-115-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-115-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-115-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-115-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
3,7-Dioxo-5b-cholan-24-oic acid
BA-116-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-116-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-116-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-116-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-116-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
3,12-Dioxo-5b-cholan-24-oic acid
BA-117-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-117-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-117-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-117-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-117-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
7,12-Dioxo-5b-cholan-24-oic acid
BA-118-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-118-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-118-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-118-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
3,6-Dioxo-5a-cholan-24-oic acid
BA-124-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-124-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-124-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-124-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
3,7-Dioxo-5a-cholan-24-oic acid
BA-125-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-125-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-125-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-125-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
3,12-Dioxo-5a-cholan-24-oic acid
BA-126-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-126-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-126-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-126-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-126-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
7,12-Dioxo-5a-cholan-24-oic acid
BA-127-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-127-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
(R)-4-((7R,8S,9S,10R,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid
(R)-4-((3R,5S,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-7-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pent-2-enoic acid
(R)-4-((5S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-3,6-dioxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid
(R)-4-((5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-3,7-dioxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid
Ala Ile Ser Val
C17H32N4O6 (388.23217320000003)
Ala Ile Val Ser
C17H32N4O6 (388.23217320000003)
Ala Leu Ser Val
C17H32N4O6 (388.23217320000003)
Ala Leu Val Ser
C17H32N4O6 (388.23217320000003)
Pregn-4-en-20-one, 3b,17-dihydroxy-6a-methyl-, 17-acetate
Pregn-4-en-20-one, 17-(acetyloxy)-3-hydroxy-6-methyl-, (3a,6a)-
Ala Ser Ile Val
C17H32N4O6 (388.23217320000003)
Ala Ser Leu Val
C17H32N4O6 (388.23217320000003)
Ala Ser Val Ile
C17H32N4O6 (388.23217320000003)
Ala Ser Val Leu
C17H32N4O6 (388.23217320000003)
Ala Thr Val Val
C17H32N4O6 (388.23217320000003)
Ala Val Ile Ser
C17H32N4O6 (388.23217320000003)
Ala Val Leu Ser
C17H32N4O6 (388.23217320000003)
Ala Val Ser Ile
C17H32N4O6 (388.23217320000003)
Ala Val Ser Leu
C17H32N4O6 (388.23217320000003)
Ala Val Thr Val
C17H32N4O6 (388.23217320000003)
Ala Val Val Thr
C17H32N4O6 (388.23217320000003)
Gly Gly Lys Lys
C16H32N6O5 (388.24340620000004)
Gly Ile Ile Ser
C17H32N4O6 (388.23217320000003)
Gly Ile Leu Ser
C17H32N4O6 (388.23217320000003)
Gly Ile Ser Ile
C17H32N4O6 (388.23217320000003)
Gly Ile Ser Leu
C17H32N4O6 (388.23217320000003)
Gly Ile Thr Val
C17H32N4O6 (388.23217320000003)
Gly Ile Val Thr
C17H32N4O6 (388.23217320000003)
Gly Lys Gly Lys
C16H32N6O5 (388.24340620000004)
Gly Lys Lys Gly
C16H32N6O5 (388.24340620000004)
Gly Leu Ile Ser
C17H32N4O6 (388.23217320000003)
Gly Leu Leu Ser
C17H32N4O6 (388.23217320000003)
Gly Leu Ser Ile
C17H32N4O6 (388.23217320000003)
Gly Leu Ser Leu
C17H32N4O6 (388.23217320000003)
Gly Leu Thr Val
C17H32N4O6 (388.23217320000003)
Gly Leu Val Thr
C17H32N4O6 (388.23217320000003)
Gly Ser Ile Ile
C17H32N4O6 (388.23217320000003)
Gly Ser Ile Leu
C17H32N4O6 (388.23217320000003)
Gly Ser Leu Ile
C17H32N4O6 (388.23217320000003)
Gly Ser Leu Leu
C17H32N4O6 (388.23217320000003)
Gly Thr Ile Val
C17H32N4O6 (388.23217320000003)
Gly Thr Leu Val
C17H32N4O6 (388.23217320000003)
Gly Thr Val Ile
C17H32N4O6 (388.23217320000003)
Gly Thr Val Leu
C17H32N4O6 (388.23217320000003)
Gly Val Ile Thr
C17H32N4O6 (388.23217320000003)
Gly Val Leu Thr
C17H32N4O6 (388.23217320000003)
Gly Val Thr Ile
C17H32N4O6 (388.23217320000003)
Gly Val Thr Leu
C17H32N4O6 (388.23217320000003)
Ile Ala Ser Val
C17H32N4O6 (388.23217320000003)
Ile Ala Val Ser
C17H32N4O6 (388.23217320000003)
Ile Gly Ile Ser
C17H32N4O6 (388.23217320000003)
Ile Gly Leu Ser
C17H32N4O6 (388.23217320000003)
Ile Gly Ser Ile
C17H32N4O6 (388.23217320000003)
Ile Gly Ser Leu
C17H32N4O6 (388.23217320000003)
Ile Gly Thr Val
C17H32N4O6 (388.23217320000003)
Ile Gly Val Thr
C17H32N4O6 (388.23217320000003)
Ile Ile Gly Ser
C17H32N4O6 (388.23217320000003)
Ile Ile Ser Gly
C17H32N4O6 (388.23217320000003)
Ile Leu Gly Ser
C17H32N4O6 (388.23217320000003)
Ile Leu Ser Gly
C17H32N4O6 (388.23217320000003)
Ile Ser Ala Val
C17H32N4O6 (388.23217320000003)
Ile Ser Gly Ile
C17H32N4O6 (388.23217320000003)
Ile Ser Gly Leu
C17H32N4O6 (388.23217320000003)
Ile Ser Ile Gly
C17H32N4O6 (388.23217320000003)
Ile Ser Leu Gly
C17H32N4O6 (388.23217320000003)
Ile Ser Val Ala
C17H32N4O6 (388.23217320000003)
Ile Thr Gly Val
C17H32N4O6 (388.23217320000003)
Ile Thr Val Gly
C17H32N4O6 (388.23217320000003)
Ile Val Ala Ser
C17H32N4O6 (388.23217320000003)
Ile Val Gly Thr
C17H32N4O6 (388.23217320000003)
Ile Val Ser Ala
C17H32N4O6 (388.23217320000003)
Ile Val Thr Gly
C17H32N4O6 (388.23217320000003)
Lys Gly Gly Lys
C16H32N6O5 (388.24340620000004)
Lys Gly Lys Gly
C16H32N6O5 (388.24340620000004)
Lys Lys Gly Gly
C16H32N6O5 (388.24340620000004)
Leu Ala Ser Val
C17H32N4O6 (388.23217320000003)
Leu Ala Val Ser
C17H32N4O6 (388.23217320000003)
Leu Gly Ile Ser
C17H32N4O6 (388.23217320000003)
Leu Gly Leu Ser
C17H32N4O6 (388.23217320000003)
Leu Gly Ser Ile
C17H32N4O6 (388.23217320000003)
Leu Gly Ser Leu
C17H32N4O6 (388.23217320000003)
Leu Gly Thr Val
C17H32N4O6 (388.23217320000003)
Leu Gly Val Thr
C17H32N4O6 (388.23217320000003)
Leu Ile Gly Ser
C17H32N4O6 (388.23217320000003)
Leu Ile Ser Gly
C17H32N4O6 (388.23217320000003)
Leu Leu Gly Ser
C17H32N4O6 (388.23217320000003)
Leu Leu Ser Gly
C17H32N4O6 (388.23217320000003)
Leu Ser Ala Val
C17H32N4O6 (388.23217320000003)
Leu Ser Gly Ile
C17H32N4O6 (388.23217320000003)
Leu Ser Gly Leu
C17H32N4O6 (388.23217320000003)
Leu Ser Ile Gly
C17H32N4O6 (388.23217320000003)
Leu Ser Leu Gly
C17H32N4O6 (388.23217320000003)
Leu Ser Val Ala
C17H32N4O6 (388.23217320000003)
Leu Thr Gly Val
C17H32N4O6 (388.23217320000003)
Leu Thr Val Gly
C17H32N4O6 (388.23217320000003)
Leu Val Ala Ser
C17H32N4O6 (388.23217320000003)
Leu Val Gly Thr
C17H32N4O6 (388.23217320000003)
Leu Val Ser Ala
C17H32N4O6 (388.23217320000003)
Leu Val Thr Gly
C17H32N4O6 (388.23217320000003)
Ser Ala Ile Val
C17H32N4O6 (388.23217320000003)
Ser Ala Leu Val
C17H32N4O6 (388.23217320000003)
Ser Ala Val Ile
C17H32N4O6 (388.23217320000003)
Ser Ala Val Leu
C17H32N4O6 (388.23217320000003)
Ser Gly Ile Ile
C17H32N4O6 (388.23217320000003)
Ser Gly Ile Leu
C17H32N4O6 (388.23217320000003)
Ser Gly Leu Ile
C17H32N4O6 (388.23217320000003)
Ser Gly Leu Leu
C17H32N4O6 (388.23217320000003)
Ser Ile Ala Val
C17H32N4O6 (388.23217320000003)
Ser Ile Gly Ile
C17H32N4O6 (388.23217320000003)
Ser Ile Gly Leu
C17H32N4O6 (388.23217320000003)
Ser Ile Ile Gly
C17H32N4O6 (388.23217320000003)
Ser Ile Leu Gly
C17H32N4O6 (388.23217320000003)
Ser Ile Val Ala
C17H32N4O6 (388.23217320000003)
Ser Leu Ala Val
C17H32N4O6 (388.23217320000003)
Ser Leu Gly Ile
C17H32N4O6 (388.23217320000003)
Ser Leu Gly Leu
C17H32N4O6 (388.23217320000003)
Ser Leu Ile Gly
C17H32N4O6 (388.23217320000003)
Ser Leu Leu Gly
C17H32N4O6 (388.23217320000003)
Ser Leu Val Ala
C17H32N4O6 (388.23217320000003)
Ser Val Ala Ile
C17H32N4O6 (388.23217320000003)
Ser Val Ala Leu
C17H32N4O6 (388.23217320000003)
Ser Val Ile Ala
C17H32N4O6 (388.23217320000003)
Ser Val Leu Ala
C17H32N4O6 (388.23217320000003)
Thr Ala Val Val
C17H32N4O6 (388.23217320000003)
Thr Gly Ile Val
C17H32N4O6 (388.23217320000003)
Thr Gly Leu Val
C17H32N4O6 (388.23217320000003)
Thr Gly Val Ile
C17H32N4O6 (388.23217320000003)
Thr Gly Val Leu
C17H32N4O6 (388.23217320000003)
Thr Ile Gly Val
C17H32N4O6 (388.23217320000003)
Thr Ile Val Gly
C17H32N4O6 (388.23217320000003)
Thr Leu Gly Val
C17H32N4O6 (388.23217320000003)
Thr Leu Val Gly
C17H32N4O6 (388.23217320000003)
Thr Val Ala Val
C17H32N4O6 (388.23217320000003)
Thr Val Gly Ile
C17H32N4O6 (388.23217320000003)
Thr Val Gly Leu
C17H32N4O6 (388.23217320000003)
Thr Val Ile Gly
C17H32N4O6 (388.23217320000003)
Thr Val Leu Gly
C17H32N4O6 (388.23217320000003)
Thr Val Val Ala
C17H32N4O6 (388.23217320000003)
Val Ala Ile Ser
C17H32N4O6 (388.23217320000003)
Val Ala Leu Ser
C17H32N4O6 (388.23217320000003)
Val Ala Ser Ile
C17H32N4O6 (388.23217320000003)
Val Ala Ser Leu
C17H32N4O6 (388.23217320000003)
Val Ala Thr Val
C17H32N4O6 (388.23217320000003)
Val Ala Val Thr
C17H32N4O6 (388.23217320000003)
Val Gly Ile Thr
C17H32N4O6 (388.23217320000003)
Val Gly Leu Thr
C17H32N4O6 (388.23217320000003)
Val Gly Thr Ile
C17H32N4O6 (388.23217320000003)
Val Gly Thr Leu
C17H32N4O6 (388.23217320000003)
Val Ile Ala Ser
C17H32N4O6 (388.23217320000003)
Val Ile Gly Thr
C17H32N4O6 (388.23217320000003)
Val Ile Ser Ala
C17H32N4O6 (388.23217320000003)
Val Ile Thr Gly
C17H32N4O6 (388.23217320000003)
Val Leu Ala Ser
C17H32N4O6 (388.23217320000003)
Val Leu Gly Thr
C17H32N4O6 (388.23217320000003)
Val Leu Ser Ala
C17H32N4O6 (388.23217320000003)
Val Leu Thr Gly
C17H32N4O6 (388.23217320000003)
Val Ser Ala Ile
C17H32N4O6 (388.23217320000003)
Val Ser Ala Leu
C17H32N4O6 (388.23217320000003)
Val Ser Ile Ala
C17H32N4O6 (388.23217320000003)
Val Ser Leu Ala
C17H32N4O6 (388.23217320000003)
Val Thr Ala Val
C17H32N4O6 (388.23217320000003)
Val Thr Gly Ile
C17H32N4O6 (388.23217320000003)
Val Thr Gly Leu
C17H32N4O6 (388.23217320000003)
Val Thr Ile Gly
C17H32N4O6 (388.23217320000003)
Val Thr Leu Gly
C17H32N4O6 (388.23217320000003)
Val Thr Val Ala
C17H32N4O6 (388.23217320000003)
Val Val Ala Thr
C17H32N4O6 (388.23217320000003)
Val Val Thr Ala
C17H32N4O6 (388.23217320000003)
1α-hydroxy-25,26,27-trinorvitamin D3 24-carboxylic acid
3α,12α-Dihydroxy-5β-chola-7,9(11)-dien-24-oic Acid
3α,12β-Dihydroxy-5β-chola-7,9(11)-dien-24-oic Acid
Cavipetin C
1alpha-hydroxy-25,26,27-trinorvitamin D3 24-carboxylic acid
ST 24:3;O4
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids 3-Oxo-7-hydroxychol-4-enoic acid is an endogenous metabolite. 3-Oxo-7-hydroxychol-4-enoic acid may be an important indicator of a poor prognosis in hepatobiliary disease[1].
3-[4-(N-Boc)piperazin-1-yl]phenylboronic acid pinacol ester
C21H33BN2O4 (388.25332480000003)
1,2-bis(ethenyl)benzene,buta-1,3-diene,methyl 2-methylprop-2-enoate,styrene
azepan-2-one,hexanedioic acid,2-piperazin-1-ylethanamine
TRANS-1-(4-PENTYLCYCLOHEXYL)-4-(2-(4-PROPOXYPHENYL)ETHYNYL)BENZENE
Galeterone
C26H32N2O (388.25145019999997)
D004791 - Enzyme Inhibitors C471 - Enzyme Inhibitor
Thiourea, N-cyclopentyl-N-[2-(5,6-dimethyl-1H-benzimidazol-2-yl)ethyl]-N-(3-methoxypropyl)- (9CI)
8,8-bis(1H-indol-3-yl)-2,6-dimethyl-2-octanol
C26H32N2O (388.25145019999997)
4-(4-Boc-piperazino)phenylboronic Acid Pinacol Ester
C21H33BN2O4 (388.25332480000003)
2-[4-(N-Boc)piperazin-1-yl]phenylboronic acid pinacol ester
C21H33BN2O4 (388.25332480000003)
(2S,4S)-1-Boc-2-(3,3-difluoropyrrolidine-1-carbonyl)-4-(1-piperazinyl)pyrrolidine
C18H30F2N4O3 (388.22858539999993)
2,8-Diazaspiro[4.5]decane-2,8-dicarboxylic acid, 2-(1,1-dimethylethyl) 8-(phenylmethyl) ester
Dehydrodeoxycholic acid
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
Anabiol
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C2360 - Anabolic Steroid
(4R)-4-[(7S,8S,9S,10R,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid
[3-carboxy-2-[(E)-11-carboxy-3-hydroxyundec-6-enoyl]oxypropyl]-trimethylazanium
C19H34NO7+ (388.23351540000004)
[3-carboxy-2-[(Z)-11-carboxy-10-hydroxyundec-9-enoyl]oxypropyl]-trimethylazanium
C19H34NO7+ (388.23351540000004)
[3-carboxy-2-[(E)-11-carboxy-3-hydroxyundec-5-enoyl]oxypropyl]-trimethylazanium
C19H34NO7+ (388.23351540000004)
[3-carboxy-2-[(E)-11-carboxy-3-hydroxyundec-4-enoyl]oxypropyl]-trimethylazanium
C19H34NO7+ (388.23351540000004)
[3-carboxy-2-[(E)-11-carboxy-3-hydroxyundec-9-enoyl]oxypropyl]-trimethylazanium
C19H34NO7+ (388.23351540000004)
[3-carboxy-2-[(E)-11-carboxy-3-hydroxyundec-8-enoyl]oxypropyl]-trimethylazanium
C19H34NO7+ (388.23351540000004)
[3-carboxy-2-[(Z)-11-carboxy-10-hydroxyundec-10-enoyl]oxypropyl]-trimethylazanium
C19H34NO7+ (388.23351540000004)
[3-carboxy-2-[(E)-11-carboxy-3-hydroxyundec-10-enoyl]oxypropyl]-trimethylazanium
C19H34NO7+ (388.23351540000004)
[3-carboxy-2-[(E)-11-carboxy-3-hydroxyundec-7-enoyl]oxypropyl]-trimethylazanium
C19H34NO7+ (388.23351540000004)
[3-Carboxy-2-(12-carboxydodecanoyloxy)propyl]-trimethylazanium
(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2,6-diaminohexanoyl]amino]-4-oxobutanoyl]amino]hexanoic acid
C16H32N6O5 (388.24340620000004)
Ala-Leu-Val-Ser
C17H32N4O6 (388.23217320000003)
A tetrapeptide composed of L-alanine, L-leucine, L-valine, and L-serine joined in sequence by peptide linkages.
(E)-1-[4-[1-(2-methylpropyl)benzimidazol-2-yl]piperazin-1-yl]-3-phenylprop-2-en-1-one
(S,R)-(furan-2,5-diyldibenzene-4,1-diyl)bis(N-cyclopropylmethanediamine)
3-(4-benzoyl-1-piperazinyl)-1-(2-methylpropyl)-6,7-dihydro-5H-cyclopenta[c]pyridine-4-carbonitrile
N-oleoyltaurine(1-)
C20H38NO4S- (388.25214080000006)
A fatty acid-taurine conjugate obtained by deprotonation of the sulfonate group of N-oleoyltaurine; major species at pH 7.3.
(13R)-13-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxotetradecanoic acid
14-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxotetradecanoic acid
2-[(1S,3S,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclohexylacetamide
(1R,9S,10S,11S)-12-(cyclopropylmethyl)-N-[3-(dimethylamino)propyl]-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
C21H32N4O3 (388.24742819999994)
N-[[(2R,3S,4S)-1-acetyl-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-2-methoxy-N-propan-2-ylacetamide
N-[[(2R,3S,4R)-1-acetyl-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-2-methoxy-N-propan-2-ylacetamide
(R)-4-((3R,5S,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-7-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pent-2-enoic acid
2-{6-Oxo-6-[4-(L-phenylalanyl)-1-piperazinyl]hexyl}guanidine
C20H32N6O2 (388.25866119999995)
N-[[(2S,3R,4S)-1-acetyl-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-2-methoxy-N-propan-2-ylacetamide
N-[[(2S,3R,4R)-1-acetyl-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-2-methoxy-N-propan-2-ylacetamide
(1S,9R,10R,11R)-12-(cyclopropylmethyl)-N-[3-(dimethylamino)propyl]-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
C21H32N4O3 (388.24742819999994)
(1R,4S,5R,9S,10S,13R,15S)-5,9-dimethyl-14-methylidene-15-(2-methylpropanoyloxy)tetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylic acid
[(2R)-3-carboxy-2-(12-carboxydodecanoyloxy)propyl]-trimethylazanium
(1S,2S,3E,7E,11E)-2,17-diacetoxycembra-3,7,11,15-tetraene
(1S,2R,3E,7E,11E)-2,17-diacetoxycembra-3,7,11,15-tetraene
(E,E)-(1R,2S,5R)-8-Phenylmenthyl 5-phenyl-2,4-pentadienoate
17alpha-Hydroxyprogesterone 3,20-bis(O-methyloxime)
2-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]oxyacetic acid
[1-carboxy-3-[3-[(E)-dec-4-enoyl]oxy-2-hydroxypropoxy]propyl]-trimethylazanium
7alpha-Hydroxy-3-oxochol-4-en-24-oic Acid
A 3-oxo Delta(4)-steroid that is 3-oxochol-4-en-24-oic acid carrying an additional 7alpha-hydroxy substituent. D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids 3-Oxo-7-hydroxychol-4-enoic acid is an endogenous metabolite. 3-Oxo-7-hydroxychol-4-enoic acid may be an important indicator of a poor prognosis in hepatobiliary disease[1].